anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Urinary tract infection (UTI) is common among older women. However, diagnosis is challenging because of frequent chronic lower urinary tract symptoms, cognitive impairment, and a high prevalence of asymptomatic bacteriuria (ASB). Current urine diagnostics lack specificity, leading to unnecessary treatment and antimicrobial resistance. This study aimed to evaluate the diagnostic accuracy of 12 urine biomarkers for diagnosing UTI in older women.
METHODS: In this case-control study, cases were women ≥65 years with ≥2 new-onset lower urinary tract symptoms, pyuria, and one uropathogen ≥104 CFU/mL. Controls were asymptomatic and classified as ASB (one uropathogen ≥105 CFU/mL), negative culture, or mixed flora. Urine biomarker concentrations were measured through liquid chromatography-mass spectrometry and ELISA. Diagnostic accuracy parameters of individual biomarkers and a biomarker model were derived from receiver operating characteristic curves.
RESULTS: We included 162 community-dwelling and institutionalized older women. Five urine inflammatory biomarkers demonstrated high discriminative ability (area under the curve ≥0.80): interleukin 6, azurocidin, neutrophil gelatinase-associated lipocalin, tissue inhibitor of metalloproteinases 2, and C-X-C motif chemokine 9. Azurocidin exhibited the highest diagnostic accuracy (sensitivity 86% [95% CI 75%-93%] and specificity 89% [95% CI 82%-94%] at 16.7 ng/mmol creatinine). A combined biomarker and pyuria model showed improved diagnostic accuracy in patients with UTI and ASB, compared with pyuria alone.
DISCUSSION: We identified several urine biomarkers that accurately differentiated older women with UTI from asymptomatic women, including ASB. These findings represent a potential advancement towards improved diagnostics for UTI in older women and warrant validation in a diverse population.
Subjects will be provided both written and verbal instructions and given a kit containing encapsulated Organic Triphala powder (Banyan Botanicals, Inc.). Subjects will take 2 grams of organic Triphala powder with a few ounces of room temperature water in the morning and at bedtime.
BACKGROUND: The hospitalization rate of ambulatory care sensitive conditions (ACSCs) has been recognized as an essential indicator reflective of the overall performance of healthcare system. At present, ACSCs has been widely used in practice and research to evaluate health service quality and efficiency worldwide. The definition of ACSCs varies across countries due to different challenges posed on healthcare systems. However, China does not have its own list of ACSCs. The study aims to develop a list to meet health system monitoring, reporting and evaluation needs in China.
METHODS: To develop the list, we will combine the best methodological evidence available with real-world evidence, adopt a systematic and rigorous process and absorb multidisciplinary expertise. Specific steps include: (1) establishment of working groups; (2) generations of the initial list (review of already published lists, semi-structured interviews, calculations of hospitalization rate); (3) optimization of the list (evidence evaluation, Delphi consensus survey); and (4) approval of a final version of China's ACSCs list. Within each step of the process, we will calculate frequencies and proportions, use descriptive analysis to summarize and draw conclusions, discuss the results, draft a report, and refine the list.
DISCUSSION: Once completed, China's list of ACSCs can be used to comprehensively evaluate the current situation and performance of health services, identify flaws and deficiencies embedded in the healthcare system to provide evidence-based implications to inform decision-makings towards the optimization of China's healthcare system. The experiences might be broadly applicable and serve the purpose of being a prime example for nations with similar conditions.
The utility model discloses a medicinal towel for haemorrhoids which is composed of a plastic bag, a radical bag, a cotton cushion and traditional Chinese medicine powder. The radical bag which is made of non-woven cloth is arranged in the plastic bag. The cotton cushion is arranged in the radical bag. The cotton cushion is provided with the traditional Chinese medicine powder made of traditional Chinese medicine, such as bletilla striata, sanguisorba, agrimony, panax pseudoginseng, etc. The medicinal towel for haemorrhoids has the advantages of simple structure, easy production, convenient use, no pains, no poison, no side effects, high curative rate, etc. The utility model is a medicinal towel for haemorrhoids which has great popularization value.
1. Open four (4) capsules and transfer contents into a clean container with a lid.
  2. Add 40 mL of water to the container.
  3. Put the lid on the container and shake to mix the capsule contents and water thoroughly for 3 minutes. 
     * NOTE: Capsule contents may not dissolve completely.
     * The prepared mixture may have visible undissolved particulates and are acceptable for administration. 
  4. Flush NG/OG tube with 5 mL of water prior to administration. 
  5. Using a catheter tip syringe, draw up the entire contents from the container and administer immediately through the NG/OG tube (12F or larger). Do not keep the mixture for future use. 
  6. If any portion of the capsule contents are left in the container, add 10 mL of water to the container, mix, and using the same syringe draw up the entire contents of the container and administer through the NG/OG (12F or larger). Repeat as needed until no capsule contents are left in the container or syringe. 
  7. Flush the NG/OG tube with 5 mL of water twice (10 mL total) after administration of the mixture.
Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
Gravity has had a significant impact on the evolution of life on Earth with organisms developing necessary biological adaptations over billions of years to counter this ever-existing force. There has been an exponential increase in experiments using real and simulated gravity environments in the recent years. Although an understanding followed by discovery of counter measures to negate diminished gravity in space had been the driving force of research initially, there has since been a phenomenal leap wherein a force unearthly as microgravity is beginning to show promising potential. The current review summarizes pathophysiological changes that occur in multiple aspects of the cardiovascular system when exposed to an altered gravity environment leading to cardiovascular deconditioning and orthostatic intolerance. Gravity influences not just the complex multicellular systems but even the survival of organisms at the molecular level by intervening fundamental cellular processes, directly affecting those linked to actin and microtubule organization via mechano-transduction pathways. The reach of gravity ranges from cytoskeletal rearrangement that regulates cell adhesion and migration to intracellular dynamics that dictate cell fate commitment and differentiation. An understanding that microgravity itself is not present on Earth propels the scope of simulated gravity conditions to be a unique and useful environment that could be explored for enhancing the potential of stem cells for a wide range of applications as has been highlighted here.
BACKGROUND: Ubiquitination is an important post-transcriptional modification crucial for maintaining cell homeostasis. As a deubiquitination enzyme, ubiquitin-specific protease 1 (USP1) is associated with tumor progression; however, its role in bladder cancer is unknown. This study aimed to analyze USP1 expression and study its roles in bladder cancer.
METHODS: The web server GEPIA was used to analyze the USP1 expression. To explore USP1's function in bladder cancer, we constructed USP1-knockout cell lines in UMUC3 cells. A FLAG-USP1 (WT USP1) plasmid and a plasmid FLAG-USP1 C90S (catalytic-inactive mutant) were used to overexpress USP1 in T24 cells. CCK8, colony formation, and Transwell assays were used to assess cell viability, proliferation, and migration. RNA-sequencing (RNA-seq) and dual-luciferase reporter assays were performed to screen the pathway. Co-immunoprecipitation and immunofluorescence were used to explore the interaction between USP1 and c-MYC. A xenograft mouse model was used to study the role of USP1 in bladder cancer.
RESULTS: USP1 expression was upregulated in human bladder cancer cells and correlated with poor patient prognosis. USP1 overexpression promoted cell proliferation, clone formation, and migration, and this was attenuated by genetic ablation of USP1. Furthermore, we observed that USP1 deficiency inhibited tumor formation in vivo. Mechanistically, the c-MYC pathway was remarkably activated compared with the other pathways. Furthermore, USP1 could interact with c-MYC and increase c-MYC's stability depending on the catalytic activity of USP1.
CONCLUSIONS: Our results suggested that high expression of USP1 promotes bladder cancer progression by stabilizing c-MYC; hence, USP1 may serve as a novel therapeutic target for treating bladder cancer.
Polymer particles each containing at least one void and also a hydrophobic copolymeric surfactant and a hydrophilic copolymeric surfactant. The hydrophobic surfactant comprises long hydrophobic chains anchored in the particles and hydrophilic chains exposed to the voids. The hydrophilic copolymeric surfactant comprises hydrophobic portions anchored in the particles and hydrophilic chains exposed to the surroundings of the particles. The particles have a fine cell structure, are washable to remove unanchored surfactant and are easily dispersible in water. They are useful in coatings, plastics, cosmetics, paper and leather. Also a process for making the particles in which water is dispersed as droplets in monomer containing the hydrophobic surfactant and the dispersion is in turn dispersed in additional water containing the hydrophilic surfactant and the whole is subjected to a polymerisation which forms particles containing voids initially filled with water.
BACKGROUND: Arterial hypertension contributes to both the development and progression of dementia due to both Alzheimer's disease (A.D.) and vascular pathology. However, the effects of different classes of anti-hypertensives (A.H.T.s), on the rate of dementia progression and brain neuropathology are unknown.
OBJECTIVE: To investigate the effect of each class of A.H.T., both as single and combined, on the rate of dementia progression. In addition, we analyzed the effect of A.H.T.s on brain neuropathology in AD participants, indicated by Braak staging, hippocampal atrophy, and baseline CSF levels of A-β42, total (T) tau, and P-181 tau.
METHODS: We have used the National Alzheimer's Coordinating Center (NACC) Uniform Data Set (UDS).
RESULTS: A.H.T.s were associated with reduced yearly increase in the CDR-SOB scores of 1.025 during a 10-year follow-up (P<0.001). The overall survival rate was higher in A.H.T. users than non-users [HR: 0.912: 0.860, 0.967) P=0.002]. These trends continued when stratifying participants by age, gender, and APOE4 allele. Participants who did not use A.H.T.s had a mean yearly increase of 1.71±1.7 in the CDR-SOB scores. This value was reduced to 1.48±1.6, P=0.006 and 1.45±1.6, P=0.024 for participants with documented use of βB and A.R.B.s, respectively. Combining diuretics with α1-AB or ACEI led to synergistic effects in reducing the rise in CDR-SOB scores. The proportion of participants who were diagnosed having AD postmortem with severe Braak staging was significantly lower in A.H.T.-users than non-users. The severity of Braak staging, and hippocampal atrophy differed in participants> 70 vs. <70 years old, in both males and females. A significant relationship was observed between hippocampal atrophy and Braak staging; and between hippocampal atrophy and baseline CSF levels of P-181 tau.
CONCLUSION: Our results could have implications for halting the progression of dementia regardless of the etiology being related to AD or vascular pathology. The choice of combination of A.H.T. therapy should also consider the combination which would lead to an optimum benefit in slowing the progression of dementia. Additionally, our results underline a more complex A.D. disease model than previously thought, which opens new treatment options.
Physical disability and poor health often accompany knee osteoarthritis (OA), particularly as people age. This decline in function and quality of life is a complex phenomenon associated with numerous factors including pain, poor physical fitness, obesity, co-morbidity, low self-efficacy and lower extremity impairments. Furthermore, the effects of age, which have not been well studied in OA, must be considered. In addition to the functional losses associated with knee OA and aging, low levels of daily physical activity and exercise are common problems in this population for whom arthritis is a major reason for activity limitation. Evidence is accumulating that exercise can enhance health and quality of life and modify a number of the factors associated with disability. There is, however, little specific information to guide exercise prescription in the diverse population of people with knee OA. Although general benefit of exercise has been demonstrated, it is time to focus research questions on the specific types of exercise that produce specific effects; and for whom particular exercises are the most useful. Additionally, exercise has shown short term benefit, but how best to maintain gains and sustain exercise behaviors in self-directed and community settings is virtually untested. These questions are relevant to all people with knee OA, and become even more important as people grow older, become more sedentary and are at greater risk for frailty, poor health and disability.

This study is designed to: determine the efficacy of specific types of exercise by examining the effects of training on physiologic adaptations and physical performance; determine the effectiveness of a comprehensive exercise protocol performed in a supervised but non-medical setting, and describe the interaction of personal characteristics and disease severity with individual response to a particular exercise regimen.
Isosorbide is hard to take because isosorbide has strong bitterness and is usually administered in a large quantity.  The object aims to formulate isosorbide into a jelly preparation which is easy to take and has an excellent drug-eluting property.  Disclosed is an isosorbide-containing jelly preparation characterized by comprising isosorbide in an amount of 65 to 75 mass% and a carrageenan component composed of ?-carrageenan and ?-carrageenan in an amount of 0.4 to 0.8 mass% both relative to the total amount of the preparation.  Also disclosed is an isosorbide-containing jelly preparation having chocolate flavor.  In the jelly preparations, the texture is good, the bitterness of isosorbide is masked, the taste is good, and the drug-eluting property is excellent.  Therefore, the jelly preparation enables isosorbide to be taken easily.  When the jelly preparation is packed in a bar-shaped bag-type package, the jelly preparation can be taken out of the package easily.
Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Participants will receive Sudapyridine (WX-081) tablets orally at a specified dose once daily for 7 days while co-administered with itraconazole (Study A) or rifampin (Study B). Pharmacokinetic sampling and safety assessments will be conducted.
The present invention relates to a method for producing coated powder for a cosmetic composition, coated powder and a cosmetic composition produced by the same. In order to make a two-phase separable cosmetic material, having a skin care effect and a makeup function, be dispersed in water and be waterproof at the same time, the method includes the steps of: firstly coating the surface of composite powder with polysaccharide; and secondly coating the surface of the composite powder with fluorine-based oil. According to the present invention, the present invention provides: the two-step powder coating method for producing the coated powder, which has excellent waterproof properties and can be dispersed in water; and a method for producing the two-phase separable type cosmetic composition. According to the present invention, provided is an attractive and visible formulation of a cosmetic material wherein power can be easily dispersed when the powder with excellent waterproof properties are inserted in to special cosmetic liquid and the powder can be separated from the cosmetic liquid as the powder is easily settled when left for a long time. The cosmetic liquid has a basic function of moisturization and skin care effects of skin wrinkle reduction, skin whitening, anti-aging, acne care, pore tightening, and so on. When applied on the skin, the coated powder provides effects of adjusting sebum, blocking UV rays, covering skin blemishes, and correcting a skin tone as makeup functions at the same time. Therefore, a user can perform basic skin care and a makeup at the same time with the coated powder.
Half-dose photodynamic therapy (HD-PDT) is administered to the patients. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689nm, and a treatment duration of 83 seconds.
The compounds can be used as preservants or as active agentsof preparation for oral cavity hygiene, deodorants andantidandruff products. They have strong antimicrobial properties,are effective against bacteria, yeasts and moulds. They can be inconcentrated, considerably non-reaction capable forms such as drypowders and non-aqeous solutions which can be diluted in order toobtain compositions of antimicrobal activity of a wide range ofoperation. The compounds contain iodide and thiocyanate anions,oxidoreductase enzyme, especially glucosaccharidase and itsrespective oxidizing substrate D-glucose. They can additionallycontain peroxidase, e.g. lactoperoxidase.
BACKGROUND: Neuropilin-1 (NRP1) is expressed on the surface epithelium of respiratory tract and immune cells, demonstrating its possible function in regulating the immune response in airway disease. However, its role in patient with chronic rhinosinusitis (CRS) remains unknown. This study aimed to elucidate the role of NRP1 in CRS with nasal polyps (CRSwNP).
METHODS: Sinonasal biopsy specimens were immunohistochemically stained to investigate NRP1 expression. Double immunofluorescence, immunoblotting, and real-time polymerase chain reaction were performed to evaluate NRP1 in primary human nasal epithelial cells (hNECs). An NRP1 inhibitor was administered to a murine nasal polyp (NP) model.
RESULTS: NRP1 was highly expressed in the epithelium in patients with CRSwNP compared to nasal tissue from controls and CRS without NP patients. NRP1 and vascular endothelial growth factor were upregulated in hNECs under hypoxia. Treatment with NRP1 inhibitor (EG00229) reduced the secretion of interleukin (IL)-1β, IL-6, IL-8, and IL-33 cytokines, as well as inducible nitric oxide synthase, cyclooxygenase-2, and prostaglandin E2 in hNECs. We found that NRP1 was highly expressed in the airway epithelium in the murine NP model. The group treated with the NRP1 inhibitor had significantly fewer nasal polypoid lesions and reduced accumulations of immune cells.
CONCLUSIONS: These findings reveal that NRP1 is upregulated in CRS and NP epithelium, and the inhibition of NRP1 may lead to a reduction in NP growth and immune cell infiltration. Our results suggest that NRP1 inhibition could be a novel possibility for treating nasal polyposis.
PROBLEM TO BE SOLVED: To produce a protein having an activity of dog IFN-γ in a large amount to bring it to be easily available and develop its use as a therapeutic agent for dogs, as a large number of tumors such as mammary gland tumor and the like, virus diseases such as parvovirus infectious disease, distemper infectious disease and the like and a large number of skin diseases are known in dogs and dog IFN-γ is considered to be especially effective as a therapeutic agent for those diseases. SOLUTION: When a useful protein is used as a medicinal agent, it is necessary to produce the protein in high purity. However, the useful protein such as cytokine and the like generally reduces its stability when it becomes highly pure. So, it is known to add a stabilizer, but it may induce immune reactions and the likes. This stabilized useful protein contains a surfactant and no other stabilizers. Cytokine is characterized in that it is a protein having activities of interferon-ω, interleukin 12 and 18, in addition especially interferon-γ and has pH 5-9. The therapeutic agents for dog diseases such as an antiviral therapeutic agent, a tumor-curing agent, an infections disease-curing agent, a skin disease-curing agent and the like contain a protein having the activity of the aforesaid stabilized dog interferon-γ.
Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
It is recommended that Rifabutin Capsules be administered at a dose of 300 mg once daily. For those patients with propensity to nausea, vomiting, or other gastrointestinal upset, administration of Rifabutin at doses of 150 mg twice daily taken with food may be useful.

For patients with severe renal impairment (creatinine clearance less than 30 mL/min), consider reducing the dose of Rifabutin by 50%, if toxicity is suspected. No dosage adjustment is required for patients with mild to moderate renal impairment. Reduction of the dose of Rifabutin may also be needed for patients receiving concomitant treatment with certain other drugs (see PRECAUTIONS- Drug Interactions). 

Mild hepatic impairment does not require a dose modification. The pharmacokinetics of rifabutin in patients with moderate and severe hepatic impairment is not known.